OrbiMed mulls raising second Israel fund

Erez Chimovits, Nissim Darvish, Anat Naschitz
Erez Chimovits, Nissim Darvish, Anat Naschitz

OrbiMed wants to raise $200-250 million, about the same as its first Israel fund, sources inform "Globes."

Leading international biomedical fund OrbiMed is considering raising a second fund in Israel. The group wants to raise $200-250 million, about the same as its first fund, according to documents obtained by "Globes."

Orbimed has not yet begun recruiting investors, but the company has already begun its preparations. Orbimed Israel is managed by Senior Managing Director Dr. Nissim Darvish and managing directors Anat Naschitz and Erez Chimovits, in partnership with OrbiMed International general partners Jonathan Silverstein and Carl Gordon. OrbiMed declined to comment on the report.

OrbiMed's first fund in Israel was founded in the framework of the government biomedical funds, with the support of the Chief Scientist. In this program, the state provided its own investment and limited the risk for the business of funds bringing to Israel experienced international parties, raising more than a minimum amount, and meeting additional rules set by the Office of the Chief Scientist. OrbiMed was the only entity meeting the tender terms in 2010, a time of crisis in the venture capital industry.

The company raised $203 million, double the required minimum. The state invested $48 million in the fund. Since no other government tender is known, it appears that OrbiMed is going to raise the capital without any governmental assistance. This can be regarded as a big success of the Chief Scientist's government funds program. While the program brought only one major venture capital fund to Israel, that fund has seen that establishing a fund in Israel can be profitable, and is continuing to invest, even without support.

Since the first government fund tender was held, the conditions for raising venture capital funds in general have improved, especially in the biomedical field. Note that OrbiMed Israel is also a partner in the Chief Scientist's biotech incubator, in partnership with international companies Johnson and Johnson and Takeda Pharmaceutical.

A young portfolio

According to the figures appearing in OrbiMed's presentation, published in preparation for the beginning of the process of raising an additional fund, the plan is to invest $5-20 million in each of 12-15 companies, the same pattern followed in the first fund. The document displays particulars of the performance of OrbiMed Israel to date. The fund invested $130 million in 19 Israeli companies, in six of which the fund has already achieved a partial or complete exit, and its internal rate of return (IRR) on its investments in Israel stands at 21.4%. Most of the exits were from investments made in Israel before the founding of the special fund for Israel, whose portfolio is still relatively young - less than two years.

The biggest exits were in Given Imaging and SuperDimension. OrbiMed invested $10 million in Given Imaging and made back $68 million over the 13 years in which Given Imaging was a listed company, until it was sold to Covidien in 2013, amounting to a 43.3% IRR. OrbiMed invested $25 million in SuperDimension, and made back $55 million in seven years, a 15.5% IRR. Another exit resulted from investments before the special fund for Israel was founded was in Predix, but the IRR on this investment was minus 5.7%.

OrbiMed Israel has already achieved partial exits in three public companies: RedHill Biopharma Ltd. (Nasdaq: RDHL); TASE: RDHL), BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX), and InspireMD Ltd. (Bulletin Board: NPSR). The return on the private companies in which the fund has invested cannot be estimated; these include Keystone Heart, CCAM, Atox Bio, Advanced Inhalation Therapies, RDD Pharma, Treato, Otic, Ornim, Nutrina, Nucleix, Medigus, and Tyto. In all, OrbiMed has invested $129 million in Israeli companies (both by the Israeli fund and before it), leaving $101 million for investment from the Israeli fund, and has received $140 million in cash in return, while the value of the additional investments (for the sake of caution, the private companies are valued according to their value when the investment was made) is $71 million. As for the planned fund, it is being set up for a relatively long 10-year period, with potential for extension. Management fees will be 2.25%.

Published by Globes [online], Israel business news - www.globes-online.com - on April 12, 2015

© Copyright of Globes Publisher Itonut (1983) Ltd. 2015

Erez Chimovits, Nissim Darvish, Anat Naschitz
Erez Chimovits, Nissim Darvish, Anat Naschitz
Inflation  credit: Tali Bogdanovsky Unexpectedly low February CPI reading cuts inflation

While inflation in Israel in the 12 months to the end of February 2025 is lower than forecast, housing prices continue to rise.

Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Competition Authority allows Delek takeover of Isracard

The Competition Authority is considered the easier of the two regulatory hurdles that the deal must overcome, the other being the Supervisor of Banks.

David Amsalem  credit  Noam Moskowitz, Knesset Spokesperson's Office Rafael to pay state NIS 444m dividend

The minister in charge of the Government Companies Authority, David Amsalem, has approved the payment by the defense company.

Barak MX air defense system  credit: IAI IAI profit jumps 55%

Israel Aerospace Industries posted a net profit of $493 million for 2024, and ended the year with an all-time high orders backlog of $25 billion.

A TSG system in tactical use  credit: PR TSG signs cooperation agreement with US defense co

The agreement includes the integration of TSG's advanced technologies into sensor-based defense systems, which will be integrated into the operational systems of US defense units.

Bria CEO Yair Adato credit: Kseniia Poliak Israeli visual generative AI co Bria raises $40m

Bria’s Visual Generative AI platform empowers businesses to create predictable, controllable, and on-brand content that aligns with their visual language.

Amnon Shashua and Aviram Ziv credit: Eyal Izhar OrCam stymied by investor dispute with Shashua

Demands by institutional investors are blocking the visual and hearing impairment device developer's recovery plan.

Work on the Green Line credit: Bar Lavi Egged wins tender to operate TA light rail Purple, Green Lines

NTA awarded the tender to Egged, which already operates the Red Line, despite government ministry opposition to one operator for the entire network.

Gabi Seroussi illustration: Gil Gibli Board chooses Seroussi as IAI chair as Erdan freezes candidacy

Israel Aerospace Industries board chose Gabi Seroussi as chair even though he did not to go through the preliminary process of the Government Companies Authority appointments review committee.

Bavli Park penthouse credit: Eyal Tagar Tel Aviv Park Bavli penthouse sells for NIS 43m

A 44th floor penthouse in one of the two towers in businessman Yitzhak Tshuva's Park Bavli project has been bought by an Israeli businessperson.

El Al aircraft  credit: Yoav Yaari El Al pilots receive nearly NIS 250,000 bonus each

Thanks to the agreements signed with the unions in 2018, El Al's employees as well as senior management share in last year's success.

Pentera CEO Amitai Ratzon credit: Eyal Izhar Israeli security validation co Pentera raises $60m

Pentera's platform enables security teams to analyze complete attack paths, identify root causes, and prioritize remediation for effective risk reduction.

Tel Aviv credit: Shutterstock Supply of unsold new homes hits record

Israel's real estate market is sliding into recession with 78,000 unsold new apartments in January, the Central Bureau of Statistics reports.

D&B chairman Doron Cohen and Meitar partner Dan Geva Meitar reclaims title of Israel's biggest law firm

Meitar has first place with 537 lawyers, followed by Herzog Fox Neeman with 512 lawyers, according to the latest Dun's 100 rankings.

First International Bank of Israel CEO Eli Cohen  credit: Eyal Toueg First Int'l posts top return on equity

First International Bank of Israel's return on equity in 2024 was 19%, the highest among Israel's banks.

Dina Ben Tal Ganancia  credit: Guy Kushi & Yariv Fein El Al almost quintuples profit

The airline posted a net profit of $545 million for 2024, 4.7 times the profit in 2023, and an all-time high.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018